Provider: View Press Release
Type: Link
Title: ViiV Healthcare announces positive data demonstrating long-acting injectable Cabenuva (cabotegravir, rilpivirine) is as effective as daily oral Biktarvy (BIC/FTC/TAF) for the treatment of HIV-1 | GSK
Description: ViiV Healthcare announced positive 12-month findings from the SOLAR study.
Provider: View Press Release
Type: Link
Title: Landmark New England Journal of Medicine publication reinforces potential of GSK’s respiratory syncytial virus older adult vaccine candidate | GSK
Description: First peer-reviewed publication of phase III RSV vaccine data in older adults, including those with comorbidities who are most at risk.
Provider: View Press Release
Type: Link
Title: ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against daily oral Biktarvy at CROI 2023 | GSK
Description: Other key data to be presented include new HIV prevention findings for long-acting cabotegravir and predictors of response to N6LS
Provider: View Press Release
Type: Link
Title: US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer | GSK
Description: Conversion from accelerated to regular (full) approval based on long-term outcomes from the GARNET phase I trial
Provider: View Press Release
Type: Link
Title: US FDA Advisory Committee votes in support of trials designed to evaluate Jemperli (dostarlimab-gxly) as a potential treatment for mismatch repair-deficient/microsatellite instability-high locally advanced rectal cancer | GSK
Description: In January 2023, the US FDA granted dostarlimab-gxly Fast Track designation for the treatment of dMMR/MSI-H locally advanced rectal cancer.
Provider: View Press Release
Type: Link
Title: GSK announces results from 17-year retrospective study on US clinical trial diversity | GSK
Description: Study examined clinical trial diversity across 495 GSK trials involving over 100,000 participants.